Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Business Strategy

Set Alert for Business Strategy

Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18

Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.

Financing Business Strategies

Structure Emerges In Obesity Race With Oral GLP-1 Agonist

Early-stage data with Structure’s oral GSBR-1290 shows weight loss of 4.9% at four weeks, which appears to top Lilly’s oral GLP-1 data in a Phase Ia trial.

Clinical Trials Business Strategies

ViiV In It For The Long Haul In HIV Market Battle With Gilead

The GSK-led joint venture has taken the lead in long-acting HIV treatment and prevention but has put back timelines on a key self-administered candidate.

Infectious Diseases Business Strategies

Bionomics Posts Positive Data In PTSD With Struggling Anxiety Drug

After failing in a Phase II trial in social anxiety disorder, Bionomics thinks mid-stage data for BNC210 in post-traumatic stress disorder may now position the drug as a novel therapy for PTSD.

Clinical Trials Business Strategies

J&J’s Rybrevant Results Provide Encouragement After Interim Analysis Sparked Jitters

The company announced topline results for MARIPOSA in EGFR-mutant NSCLC, showing positive progression-free survival and a favorable trend on overall survival.

Clinical Trials ImmunoOncology

Blueprint’s Evolution On Its Path To Financial Sustainability

Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.

Launches Business Strategies

Avalyn Raises $175m To Fund Inhaled Versions Of Pulmonary Fibrosis Drugs

Financing Snapshot: Seattle biotech claims its targeted, inhalable versions of Esbriet and Ofev, both oral IPF drugs, may offer better tolerability and stronger efficacy than established products.

Financing Business Strategies

The Game Looks Up For Galecto

The Boston-based biotech is weighing up its options as the fall-out from its failed IPF candidate casts a shadow over Galecto’s future.

Restructuring Business Strategies

Ionis Closer To First Wholly-Owned Drug Launch With Olezarsen Phase III Success

Ionis will seek US and EU approvals to treat familial chylomicronemia syndrome in the first half of 2024. Phase III data in the larger severe hypertriglyceridemia indication are due in late 2024 or early 2025.

Clinical Trials Rare Diseases

Asia Deal Watch: Inventiva Finds Japan/Korea Partner For Phase III NASH Candidate In Hepalys

Plus deals involving SK pharmteco/CBM, Kezar/Everest, Cerecin/University of Alberta, PeptiDream/Genentech, Aclipse/Chong Kun Dang and Cure Genetics/Frametact.

Deal Watch Business Strategies

Italy’s Alfasigma Comes Calling After Intercept’s Cruel Summer

The Bologna-based firm is looking to grow its presence in the US as well as in gastrointestinal and liver disease as it acquires Intercept, which received a second rejection for its NASH drug OCA in June.

M & A Deals

What Verona Needs To Make COPD Drug Ensifentrine A Success

Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.

Respiratory Business Strategies
See All
UsernamePublicRestriction

Register